Abstract
The development of potential neuroprotective therapies for neurodegenerative diseases (Parkinsons and Alzheimers Disease) must be based on understanding their molecular and biochemical pathogenesis. Many potential pathways of neuronal cell death have been implicated in a mouse model of neurodegenerative disease, including excitotoxicity, toxicity from reactive oxygen species (superoxide anion, nitric oxide, hydroxyl radical), apoptosis (caspase-dependent and -independent pathways), necrosis and glial injury. Some agents that act on these pathways may be available for protecting the brain against chronic neurodegenerative conditions like Parkinsons and Alzheimers disease. Drugs currently used to treat neurological disease and injuries provide temporary relief of symptoms but do not stop or slow the underlying neurodegenerative process. Restorative therapies for Parkinsons Disease are currently focused on cell replacement and administration of growth factors and small-molecule neurotrophic agents. The new experimental drugs, by contrast, target the common, underlying cause of destructive process of brain cell death. For example, p53 inhibitors attack a key protein involved in nerve cell death and represent a new strategy for preserving brain function following sudden injury or chronic disease. Analogues of pifithrin-alpha (PFT), which was shown in previous studies to inhibit p53, were designed, synthesized and tested to see whether they would work against cultured brain cells and animal models of neurodegenerative disease. Moreover, several agents based on the predominant anti-amyloid strategy, targeting amyloid-beta (Aβ) peptide, which aggregates in the plaques that are a hallmark of Alzheimers disease, would affect disease progression. Researchers are already making great strides in developing a vaccine for this progressive brain disorder. Immunization could offer a way to blunt or even prevent the deadly, memory-robbing disease. Here we review many of potential neuroprotective therapies, and strategies that might be suited to the development of innovative approaches that prevent degeneration and restore function in Parkinsons disease.
Keywords: Parkinson`s disease, Alzheimer, glial injury
Current Medicinal Chemistry
Title:New Therapeutic Strategy for Parkinson’s and Alzheimer’s Disease
Volume: 17 Issue: 25
Author(s): E. Esposito and S. Cuzzocrea
Affiliation:
Keywords: Parkinson`s disease, Alzheimer, glial injury
Abstract: The development of potential neuroprotective therapies for neurodegenerative diseases (Parkinsons and Alzheimers Disease) must be based on understanding their molecular and biochemical pathogenesis. Many potential pathways of neuronal cell death have been implicated in a mouse model of neurodegenerative disease, including excitotoxicity, toxicity from reactive oxygen species (superoxide anion, nitric oxide, hydroxyl radical), apoptosis (caspase-dependent and -independent pathways), necrosis and glial injury. Some agents that act on these pathways may be available for protecting the brain against chronic neurodegenerative conditions like Parkinsons and Alzheimers disease. Drugs currently used to treat neurological disease and injuries provide temporary relief of symptoms but do not stop or slow the underlying neurodegenerative process. Restorative therapies for Parkinsons Disease are currently focused on cell replacement and administration of growth factors and small-molecule neurotrophic agents. The new experimental drugs, by contrast, target the common, underlying cause of destructive process of brain cell death. For example, p53 inhibitors attack a key protein involved in nerve cell death and represent a new strategy for preserving brain function following sudden injury or chronic disease. Analogues of pifithrin-alpha (PFT), which was shown in previous studies to inhibit p53, were designed, synthesized and tested to see whether they would work against cultured brain cells and animal models of neurodegenerative disease. Moreover, several agents based on the predominant anti-amyloid strategy, targeting amyloid-beta (Aβ) peptide, which aggregates in the plaques that are a hallmark of Alzheimers disease, would affect disease progression. Researchers are already making great strides in developing a vaccine for this progressive brain disorder. Immunization could offer a way to blunt or even prevent the deadly, memory-robbing disease. Here we review many of potential neuroprotective therapies, and strategies that might be suited to the development of innovative approaches that prevent degeneration and restore function in Parkinsons disease.
Export Options
About this article
Cite this article as:
Esposito E. and Cuzzocrea S., New Therapeutic Strategy for Parkinson’s and Alzheimer’s Disease, Current Medicinal Chemistry 2010; 17 (25) . https://dx.doi.org/10.2174/092986710791859324
DOI https://dx.doi.org/10.2174/092986710791859324 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
Call for Papers in Thematic Issues
Advances in Medicinal Chemistry: From Cancer to Chronic Diseases.
The broad spectrum of the issue will provide a comprehensive overview of emerging trends, novel therapeutic interventions, and translational insights that impact modern medicine. The primary focus will be diseases of global concern, including cancer, chronic pain, metabolic disorders, and autoimmune conditions, providing a broad overview of the advancements in ...read more
Approaches to the treatment of chronic inflammation
Chronic inflammation is a hallmark of numerous diseases, significantly impacting global health. Although chronic inflammation is a hot topic, not much has been written about approaches to its treatment. This thematic issue aims to showcase the latest advancements in chronic inflammation treatment and foster discussion on future directions in this ...read more
Cellular and Molecular Mechanisms of Non-Infectious Inflammatory Diseases: Focus on Clinical Implications
The Special Issue covers the results of the studies on cellular and molecular mechanisms of non-infectious inflammatory diseases, in particular, autoimmune rheumatic diseases, atherosclerotic cardiovascular disease and other age-related disorders such as type II diabetes, cancer, neurodegenerative disorders, etc. Review and research articles as well as methodology papers that summarize ...read more
Chalcogen-modified nucleic acid analogues
Chalcogen-modified nucleosides, nucleotides and oligonucleotides have been of great interest to scientific research for many years. The replacement of oxygen in the nucleobase, sugar or phosphate backbone by chalcogen atoms (sulfur, selenium, tellurium) gives these biomolecules unique properties resulting from their altered physical and chemical properties. The continuing interest in ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Role of Catechol-O-Methyltransferase (COMT)-Dependent Processes in Parkinson’s Disease and L-DOPA Treatment
CNS & Neurological Disorders - Drug Targets Basic Pharmacology of NMDA Receptors
Current Pharmaceutical Design Restless Legs Syndrome/Willis-Ekbom Disease and Periodic Limb Movements: A Comprehensive Review of Epidemiology, Pathophysiology, Diagnosis and Treatment Considerations
Current Rheumatology Reviews Recent Evidence Regarding a Role for Cdk5 Dysregulation in Alzheimers Disease
Current Alzheimer Research Partial Dopamine Agonists and the Treatment of Psychosis
Current Neuropharmacology Mechanisms of Action of Antipsychotic Drugs of Different Classes, Refractoriness to Therapeutic Effects of Classical Neuroleptics, and Individual Variation in Sensitivity to their Actions: PART II
Current Neuropharmacology Oxidative Stress and Psychological Disorders
Current Neuropharmacology The Paths to Neurodegeneration in Genetic Parkinson's Disease
CNS & Neurological Disorders - Drug Targets Current Pharmaceutical Treatments and Alternative Therapies of Parkinson’s Disease
Current Neuropharmacology Computational Study of Human Tyrosine Hydroxylase Mutants to Uphold [4-(Propan-2-yl) Phenyl]Carbamic Acid as a Potential Inhibitor
CNS & Neurological Disorders - Drug Targets Haloperidol Cytotoxicity and Its Relation to Oxidative Stress
Mini-Reviews in Medicinal Chemistry Calpain as a Potential Therapeutic Target in Parkinsons Disease
CNS & Neurological Disorders - Drug Targets Transcranial Magnetic Stimulation of Degenerating Brain: A Comparison of Normal Aging, Alzheimer’s, Parkinson’s and Huntington's Disease
Current Alzheimer Research Will it Ever Become Possible to Prevent Dopaminergic Neuronal Degeneration?
CNS & Neurological Disorders - Drug Targets Antipsychotics and Cognitive Functioning: A Critical Review
Current Psychopharmacology Nitric Oxide in Health and Disease from the Point of View of the Otorhinolaryngologist
Current Pharmaceutical Design Neurotrophic Factors as a Protective Strategy in Parkinsons Disease
CNS & Neurological Disorders - Drug Targets Intrahypothalamic Administration of Modafinil Increases Expression of MAP-Kinase in Hypothalamus and Pons in Rats
CNS & Neurological Disorders - Drug Targets On the Diversity of Oxidative Bioactivation Reactions on Nitrogen- Containing Xenobiotics
Current Drug Metabolism Homology Modeling of Adenosine A2A Receptor and Molecular Docking for Exploration of Appropriate Potent Antagonists for Treatment of Parkinsons Disease
Current Aging Science